Related Experiment Video

Updated: Oct 28, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

717

Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?

Liliana Fonseca1, Cláudia Freitas1, Ana Caramelo2

  • 1Endocrinology, Diabetes and Metabolism Department Centro Hospitalar e Universitário do Porto Porto Portugal.

Endocrinology, Diabetes & Metabolism
|July 19, 2021
PubMed

Insights

High PD-L1 expression was found in medullary thyroid cancer (MTC) tissues. This suggests that immune checkpoint inhibitor immunotherapy, like pembrolizumab, may be a viable treatment option for MTC patients.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Medullary thyroid cancer (MTC) treatment remains a challenge.
  • Investigating programmed death-ligand 1 (PD-L1) expression is crucial for exploring novel therapeutic strategies.

Discussion:

  • This study evaluated PD-L1 expression in MTC tumor tissues using an anti-PD-L1 22C3 antibody.
  • A high PD-L1 expression rate of 75% (6 out of 8 patients) was observed.
  • These findings align with two other recent studies reporting elevated PD-L1 levels in MTC.

Key Insights:

  • Medullary thyroid cancer cells exhibit significant PD-L1 expression.
  • This expression supports the potential efficacy of immunotherapy targeting PD-1/PD-L1 pathways.

Outlook:

  • Immunotherapy, specifically agents like pembrolizumab, could represent a promising therapeutic avenue for MTC.
  • Further research is warranted to confirm the clinical benefit of immunotherapy in MTC treatment.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K